O1-07-06: Hippocampal sparing and limbic predominant tau subtypes of Alzheimer's disease determined in vivo using [18F]-AV-1451 PET imaging

2015 ◽  
Vol 11 (7S_Part_3) ◽  
pp. P144-P145 ◽  
Author(s):  
Adam J. Schwarz ◽  
Sergey Shcherbinin ◽  
Bradley B. Miller ◽  
Peng Yu ◽  
Michael Navitsky ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Hippocampal Sparing

[IC-P-178]: HEAD-TO-HEAD IN VIVO COMPARISON OF TAU-SPECIFIC PET TRACERS IN ALZHEIMER's DISEASE: [11 C]THK5351 VERSUS [11 C]PBB3 PET IMAGING

2017 ◽  
Vol 13 (7S_Part_2) ◽  
pp. P133-P133 ◽  
Author(s):  
Konstantinos Chiotis ◽  
Per Stenkrona ◽  
Ove Almkvist ◽  
Ryosuke Arakawa ◽  
Akihiro Takano ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Pet Tracers

[P3-338]: IN VIVO TAU PET IMAGING IN EARLY-ONSET ALZHEIMER's DISEASE AND LATE-ONSET ALZHEIMER's DISEASE

2017 ◽  
Vol 13 (7S_Part_22) ◽  
pp. P1083-P1083
Author(s):  
Young Noh ◽  
Han Kyu Na ◽  
Seongho Seo ◽  
Sang-Yoon Lee ◽  
Hye Jin Jeong ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Early Onset ◽  
Late Onset ◽  
Early Onset Alzheimer’S Disease ◽  
Tau Pet ◽  
Tau Pet Imaging

[P2-366]: HEAD-TO-HEAD IN VIVO COMPARISON OF TAU-SPECIFIC PET TRACERS IN ALZHEIMER's DISEASE: [11 C]THK5351 VERSUS [11 C]PBB3 PET IMAGING

2017 ◽  
Vol 13 (7S_Part_15) ◽  
pp. P765-P765 ◽  
Author(s):  
Konstantinos Chiotis ◽  
Per Stenkrona ◽  
Ove Almkvist ◽  
Ryosuke Arakawa ◽  
Akihiro Takano ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Pet Tracers

scholarly journals Imaging beta-amyloid (Aβ) burden in the brains of middle-aged individuals with alcohol-use disorders: a [11C]PIB PET study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Margaret R. Flanigan ◽  
Sarah K. Royse ◽  
David P. Cenkner ◽  
Katelyn M. Kozinski ◽  
Clara J. Stoughton ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Alcohol Use ◽  
Cortical Thickness ◽  
Pet Imaging ◽  
Healthy Controls ◽  
Middle Aged ◽  
Neurocognitive Dysfunction ◽  
Amyloid Aβ

AbstractNo in vivo human studies have examined the prevalence of Alzheimer’s disease (AD) neuropathology in individuals with alcohol-use disorder (AUD), although recent research suggests that a relationship between the two exists. Therefore, this study used Pittsburgh Compound-B ([11C]PiB) PET imaging to test the hypothesis that AUD is associated with greater brain amyloid (Aβ) burden in middle-aged adults compared to healthy controls. Twenty healthy participants (14M and 6F) and 19 individuals with AUD (15M and 4F), all aged 40–65 years, underwent clinical assessment, MRI, neurocognitive testing, and positron emission tomography (PET) imaging. Global [11C]PiB standard uptake value ratios (SUVRs), cortical thickness, gray matter volumes (GMVs), and neurocognitive function in subjects with AUD were compared to healthy controls. These measures were selected because they are considered markers of risk for future AD and other types of neurocognitive dysfunction. The results of this study showed no significant differences in % global Aβ positivity or subthreshold Aβ loads between AUD and controls. However, relative to controls, we observed a significant 6.1% lower cortical thickness in both AD-signature regions and in regions not typically associated with AD, lower GMV in the hippocampus, and lower performance on tests of attention as well as immediate and delayed memory in individuals with AUD. This suggest that Aβ accumulation is not greater in middle-aged individuals with AUD. However, other markers of neurodegeneration, such as impaired memory, cortical thinning, and reduced hippocampal GMV, are present. Further studies are needed to elucidate the patterns and temporal staging of AUD-related pathophysiology and cognitive impairment. Imaging β-amyloid in middle age alcoholics as a mechanism that increases their risk for Alzheimer’s disease; Registration Number: NCT03746366.

Tau Subtypes of Alzheimer’s Disease Determined in vivo Using Flortaucipir PET Imaging

2019 ◽  
Vol 71 (3) ◽  
pp. 1037-1048 ◽  
Author(s):  
Arnaud Charil ◽  
Sergey Shcherbinin ◽  
Sudeepti Southekal ◽  
Michael D. Devous ◽  
Mark Mintun ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging

scholarly journals The cholinergic system in subtypes of Alzheimer’s disease: an in vivo longitudinal MRI study

2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Alejandra Machado ◽  
◽  
Daniel Ferreira ◽  
Michel J. Grothe ◽  
Helga Eyjolfsdottir ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Basal Forebrain ◽  
Cholinergic System ◽  
Structural Mri ◽  
Specific Response ◽  
Healthy Controls ◽  
Hippocampal Sparing

Abstract Background The heterogeneity within Alzheimer’s disease (AD) seriously challenges the development of disease-modifying treatments. We investigated volume of the basal forebrain, hippocampus, and precuneus in atrophy subtypes of AD and explored the relevance of subtype stratification in a small clinical trial on encapsulated cell biodelivery (ECB) of nerve growth factor (NGF) to the basal forebrain. Methods Structural MRI data was collected for 90 amyloid-positive patients and 69 amyloid-negative healthy controls at baseline, 6-, 12-, and 24-month follow-up. The effect of the NGF treatment was investigated in 10 biopsy-verified AD patients with structural MRI data at baseline and at 6- or 12-month follow-up. Patients were classified as typical, limbic-predominant, hippocampal-sparing, or minimal atrophy AD, using a validated visual assessment method. Volumetric analyses were performed using a region-of-interest approach. Results All AD subtypes showed reduced basal forebrain volume as compared with the healthy controls. The limbic-predominant subtype showed the fastest basal forebrain atrophy rate, whereas the minimal atrophy subtype did not show any significant volume decline over time. Atrophy rates of the hippocampus and precuneus also differed across subtypes. Our preliminary data from the small NGF cohort suggest that the NGF treatment seemed to slow the rate of atrophy in the precuneus and hippocampus in some hippocampal-sparing AD patients and in one typical AD patient. Conclusions The cholinergic system is differentially affected in distinct atrophy subtypes of AD. Larger studies in the future should confirm that this differential involvement of the cholinergic system may contribute to subtype-specific response to cholinergic treatment. Our preliminary findings suggest that future clinical trials should target specific subtypes of AD, or at least report treatment effects stratified by subtype. Trial registration ClinicalTrials.gov identifier: NCT01163825. Registered 14 July 2010.

scholarly journals Brain energy metabolism and neuroinflammation in ageing APP/PS1-21 mice using longitudinal 18F-FDG and 18F-DPA-714 PET imaging

2016 ◽  
Vol 37 (8) ◽  
pp. 2870-2882 ◽  
Author(s):  
Jatta S Takkinen ◽  
Francisco R López-Picón ◽  
Rana Al Majidi ◽  
Olli Eskola ◽  
Anna Krzyczmonik ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Energy Metabolism ◽  
Pet Imaging ◽  
Ex Vivo ◽  
Underlying Disease ◽  
Brain Energy Metabolism ◽  
Model Of Alzheimer’S Disease ◽  
Brain Energy

Preclinical animal model studies of brain energy metabolism and neuroinflammation in Alzheimer’s disease have produced conflicting results, hampering both the elucidation of the underlying disease mechanism and the development of effective Alzheimer’s disease therapies. Here, we aimed to quantify the relationship between brain energy metabolism and neuroinflammation in the APP/PS1-21 transgenic mouse model of Alzheimer’s disease using longitudinal in vivo18F-FDG and 18F-DPA-714) PET imaging and ex vivo brain autoradiography. APP/PS1-21 (TG, n = 9) and wild type control mice (WT, n = 9) were studied longitudinally every third month from age 6 to 15 months with 18F-FDG and 18F-DPA-714 with a one-week interval between the scans. Additional TG (n = 52) and WT (n = 29) mice were used for ex vivo studies. In vivo, the 18F-FDG SUVs were lower and the 18F-DPA-714 binding ratios relative to the cerebellum were higher in the TG mouse cortex and hippocampus than in WT mice at age 12 to 15 months ( p < 0.05). The ex vivo cerebellum binding ratios supported the results of the in vivo18F-DPA-714 studies but not the 18F-FDG studies. This longitudinal PET study demonstrated decreased energy metabolism and increased inflammation in the brains of APP/PS1-21 mice compared to WT mice.

The imaging features and clinical associations of a novel tau PET tracer - 18F-APN1607(18F-PM-PBB3) in Alzheimer’s disease

2020 ◽  
Author(s):  
Jung Lung Hsu ◽  
Kun-Ju Lin ◽  
Ing-Tsung Hsiao ◽  
Kuo-Lun Huang ◽  
Chi-Hung Liu ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Standardized Uptake Value ◽  
Gender Effects ◽  
Imaging Features ◽  
Cognitive Changes ◽  
Posterior Cingulate ◽  
Tau Pet

Abstract Background: In vivo tau positron emission tomography (PET) imaging could help clarify the spatial distribution of tau deposition in Alzheimer’s disease (AD) and aid in the differential diagnosis of tauopathies. To date, there have been no in vivo 18 F-APN1607 tau PET studies in patients with AD.Methods: We applied tau tracer in twelve normal controls (NCs) and ten patients in the mild to moderate stage of probable AD. Detailed clinical information, cognitive measurements and disease severity were documented. Regional standardized uptake value ratios (SUVRs) from 18 F-AV-45 (florbetapir), 18 F-APN1607 PET images and regional gray matter (GM) atrophic ratios were calculated for further analysis.Results: Quantitative analyses showed significantly elevated SUVRs in the frontal, temporal, parietal, occipital lobes, anterior and posterior cingulate gyri, precuneus, and parahippocampal region (all ps < 0.01) with medium to large effect sizes (0.44 - 0.75). The SUVRs from 18 F-APN1607 PET imaging showed significant correlations with the ADAS-cog scores (all ps < 0.01) and strong correlation coefficients (R squared ranged from 0.54 to 0.68), even adjusted for age and gender effects. Finally, the SUVRs from 18 F-APN1607 PET imaging of the parahippocampal region showed rapid saturation as the ADAS-cog scores increased, and the SUVRs of the posterior cingulate gyrus and the temporal, frontal, parietal and occipital regions slowly increased. The combined SUVRs from 18 F-AV-45 PET, 18 F-APN1607 PET and regional GM atrophic ratio showed that uptake associated with the amyloid burden rapidly increased and reach a plateau, whereas uptake associated with tau depositions increased slowly and finally followed by regional GM atrophic ratios in most regions as the ADAS-cog scores increased. However, different regions exhibited various combinations of these patterns.Conclusions: Our findings suggest that the 18 F-APN1607 tau tracer showed a clear background without significant uptake in the basal ganglia or midbrain. Uptake of this tracer correlated well with cognitive changes and demonstrated the spatial pattern of amyloid, tau deposition and GM atrophy in the progression of AD. Thus, the regional base of dynamic biomarker changes was observed in the current study.Trial registration: registration number (NCT03625128), date of registration( August 10, 2018), retrospectively registered.

Sign in / Sign up

Export Citation Format

Share Document